# Exploring the Therapeutic Potential of MOTS-c in Autism Spectrum Disorder

Canonical source: https://retacompare.com/research/exploring-the-therapeutic-potential-of-mots-c-in-autism-spectrum-disorder

Mitochondrial & Longevity · 2026-02-18


    MOTS-c shows promise as a therapeutic candidate for alleviating autism-like behaviors. This peptide, derived from mitochondria, may help mitigate oxidative stress associated with autism spectrum disorder (ASD). The study investigates its effects in a valproic acid-induced rat model of autism, highlighting its potential to influence neuroprotective and antioxidant pathways.

What this study examined

The research focused on the therapeutic effects of MOTS-c in a rat model of autism induced by valproic acid. Pregnant Sprague-Dawley rats were administered either valproic acid or saline on embryonic day 12. The offspring, both male and female, received intraperitoneal injections of 0.5 mg/kg/day MOTS-c or saline from postnatal days 21 to 46. Behavioral testing was conducted, followed by histological and biochemical analyses to assess the impact of MOTS-c on autism-like behaviors and associated neurobiological changes.

Why it matters for MOTS-c research

This study is significant for MOTS-c research as it explores its potential role in addressing ASD, a condition with limited treatment options. The findings suggest that MOTS-c may offer a novel approach to managing symptoms related to oxidative stress and neurodevelopmental disorders. By mimicking the effects of exercise through AMPK activation, MOTS-c could provide a non-invasive therapeutic strategy for individuals with ASD.

Key findings

Valproic acid exposure in rats led to impaired sociability and repetitive behaviors.

Increased oxidative stress and neuronal damage were observed in the prefrontal cortex of affected rats.

MOTS-c treatment reversed several autism-like behaviors, including sociability and repetitive actions.

No significant changes in plasma levels of tetrahydrobiopterin (BH4) or brain-derived neurotrophic factor (BDNF) were detected post-treatment.

MOTS-c exhibited neuroprotective and antioxidant effects independent of BH4 and BDNF.

Despite improvements, MOTS-c did not significantly affect anxiety levels or neocortical damage.

How MOTS-c works (background)

MOTS-c is a mitochondrial-derived peptide that plays a role in regulating metabolic processes and cellular stress responses. It activates AMP-activated protein kinase (AMPK), a key regulator of energy homeostasis, which has been shown to alleviate oxidative stress. The peptide's ability to mimic exercise effects positions it as a potential therapeutic agent in conditions where exercise adherence is challenging, such as in individuals with ASD. By enhancing neuroprotection and reducing oxidative damage, MOTS-c may contribute to improved behavioral outcomes in autism models.

Practical takeaways for researchers

Researchers exploring MOTS-c should consider its dual role as an antioxidant and neuroprotective agent. The findings from this study indicate that MOTS-c could be a viable candidate for further investigation in clinical settings, particularly in the context of neurodevelopmental disorders like ASD. Future studies should focus on elucidating the precise mechanisms through which MOTS-c exerts its effects and explore its potential in combination with other therapeutic strategies. Additionally, understanding the peptide's pharmacokinetics and optimal dosing will be crucial for translating these findings into clinical practice.

FAQ

What is MOTS-c?

MOTS-c is a mitochondrial-derived peptide involved in regulating metabolism and cellular stress responses.

How does MOTS-c affect autism-like behaviors?

In studies, MOTS-c has shown potential in reversing certain autism-like behaviors in animal models, possibly through its neuroprotective and antioxidant properties.

Are there any side effects associated with MOTS-c?

Current research on MOTS-c is still in early stages, and while no significant adverse effects have been reported in studies, further investigation is needed to fully understand its safety profile.

Source: PubMed · Mol Neurobiol · published 2026-02-18.

## Sources

- PubMed · Mol Neurobiol: https://pubmed.ncbi.nlm.nih.gov/41706383/